Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis.

"People living with psoriatic arthritis cope with symptoms like pain, joint swelling and irreversible joint damage that may interfere with their daily activities," said Atul Deodhar, MD, MRCP, FACP, ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

First-line treatment with TREMFYA ® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...

Please provide your email address to receive an email when new articles are posted on . After three doses of guselkumab, 60% of participants had clinically meaningful improvement in psoriatic ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had ...

The recommended dosage for active PsA and moderate to severe plaque PsO in pediatric patients 6 years (≥40kg) is 100mg administered SC at week 0, 4, and then every 8 weeks thereafter. The Food and ...

IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced new data from the Phase 3b APEX study showing that Tremfya continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and ...